Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)

Table 2 Disease characteristics of patients who underwent haematopoietic stem cell transplant (HSCT).

Patient no.	Age (years)	Gender	Diagnosis, stage^a	Paraprotein type	Bence-Jones	Prior treatment	Status^b	Melphalan dose (mg/kg)
SC001	61	M	Multiple myeloma, III-A	IgG κ	Not present	VAD, CAD	Partial response	3.92
SC002	62	F	Multiple myeloma, III-A	IgG κ	Present	VAD, CAD	Progressive disease	5.61
SC003	50	M	Multiple myeloma, III-A	Light chain κ	Present	VAD, CAD	Minimal response	5.19
SC004	55	M	Multiple myeloma, III-A	IgG κ, light chain κ	Not present	VAD, CAD	Partial response	5.13
SC005	45	M	Multiple myeloma, III-A	Light chain κ	Present	PAD, CAD	Partial response	6.25
SC006	39	M	Multiple myeloma, III-B	IgG κ	Not present	VAD, CAD	Minimal response	4.37
SC007	54	M	Multiple myeloma, II-A	IgG κ	Not present	Thalidomide, dexamethasone, CAD	Stable disease	5.07
SC008	61	M	Lymphoplasmocytic lymphoma, IV-A	IgG κ, light chain κ	Present	VAD, CAD	Minimal response	5.13

^aStaging by Durie and Salmon criteria [41]; ^bstatus after previous treatment by International Bone Marrow Transplant Registry and Autologous Blood, and Marrow Transplant Registry criteria [42].
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CAD = cyclophosphamide, adriamycin, dexamethasone; PAD = bortezomib, adriamycin, dexamethasone; VAD = vincristine, adriamycin, dexamethasone.

ISSN: 1741-7015